The findings of this study could lead to a new therapeutic strategy for acute myeloid leukemia for the first time in four decades BUSAN, South Korea, February 1, 2023 /PRNewswire/ — Leukemia, a type of blood cancer, affected an estimated 2.3 million people worldwide in 2015. Acute myeloid leukemia (AML)—a particularly aggressive disease—generally begins in …
Researchers at Pusan National University found that suppressing SURF4 expression reduces pathological processes that contribute to leukemia progression. Credit: Professor Dongjun Lee, Pusan National University Leukemia, a type of blood cancer, affected an estimated 2.3 million people worldwide in 2015. Acute myeloid leukemia (AML)—a particularly aggressive disease—generally begins in the bone marrow, when stem cells …
Vincerx’s proprietary carrier and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significantly improved safety in non-human primates (NHPs) compared to Mylotarg™ (gemtuzumab ozogamicin). VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine …
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in AML xenograft models KT-253 showed combinatorial benefit with the BCL-2 inhibitor venetoclax in a model of venetoclax-resistant AML KT-253 is also active in other hematologic malignancies including DLBCL WATERTOWN, Massachusetts, Dec. 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, …